Literature DB >> 24176567

Surgery versus SABR for NSCLC.

Alexander V Louie1, Sasha Senthi, David A Palma.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24176567     DOI： 10.1016/S1470-2045(13)70446-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  8 in total

1.  Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada.

Authors:  Alexander V Louie; George B Rodrigues; David A Palma; Suresh Senan
Journal:  Oncologist       Date:  2014-06-20

2.  Differentially expressed protein-coding genes and long noncoding RNA in early-stage lung cancer.

Authors:  Ming Li; Mantang Qiu; Youtao Xu; Qixing Mao; Jie Wang; Gaochao Dong; Wenjia Xia; Rong Yin; Lin Xu
Journal:  Tumour Biol       Date:  2015-07-16

3.  Survey of stereotactic ablative body radiotherapy in the UK by the QA group on behalf of the UK SABR Consortium.

Authors:  G Distefano; A Baker; A J D Scott; G J Webster
Journal:  Br J Radiol       Date:  2014-03-13       Impact factor: 3.039

Review 4.  Stereotactic radiotherapy for early lung cancer: Evidence-based approach and future directions.

Authors:  Samer Chehade; David A Palma
Journal:  Rep Pract Oncol Radiother       Date:  2014-12-12

5.  Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future?

Authors:  Luca Bertolaccini; Alberto Terzi; Francesco Ricchetti; Filippo Alongi
Journal:  Ann Transl Med       Date:  2015-02

6.  A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer.

Authors:  Christopher Cao; Daniel Wang; Caroline Chung; David Tian; Andreas Rimner; James Huang; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2018-09-15       Impact factor: 5.209

7.  Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancer.

Authors:  Naomi E Verstegen; Alexander P W M Maat; Frank J Lagerwaard; Marinus A Paul; Michel I Versteegh; Joris J Joosten; Willem Lastdrager; Egbert F Smit; Ben J Slotman; Joost J M E Nuyttens; Suresh Senan
Journal:  Radiat Oncol       Date:  2016-10-03       Impact factor: 3.481

8.  Outcomes of SBRT for lung oligo-recurrence of non-small cell lung cancer: a retrospective analysis.

Authors:  Qingren Lin; Ning Zhou; Xiang Zhu; Juan Lin; Jun Fang; Feiying Gu; Xiaojiang Sun; Yuezhen Wang
Journal:  J Radiat Res       Date:  2022-03-17       Impact factor: 2.724
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.